About

Partnering

At Zumutor , we have developed two antibody engineering platforms to facilitate our program for discovery and development of  immunotherapies that have the potential to be novel best-in-class monotherapies, and core components of innovative combination treatments.
We are committed to partnering with global biopharmaceutical companies for early stage licensing of our pipeline and to jointly discover and develop innovative products.
We have licensed our biologic product for treatment of breast cancer and are engaged in collaborations and related to our technology platforms.
For additional information on partnering with Zumutor, please contact our business development team at kavithaiyer.rodrigues@zumutor.com

–

Syngene International, a leading global Contract Research Services Company, has entered into a non-exclusive partnering agreement with Zumutor Biologics, an emerging immunooncology Company, to access Zumutor’s proprietary naïve human phage/yeast display library. This collaboration further enhances Syngene’s market-leading capabilities in Discovery Biology, providing its scientists with additional tools to help solve complex biology problems in biotherapeutic drug discovery

–

On 12 November, 2019 Zumutor Biologics and Prof. Vijay Kuchroo Laboratory (Evergrande Center for Immunologic Diseases at Harvard Medical School and Brigham and Women’s Hospital Ann Romney Center for Neurologic Diseases) have inked an agreement to discover unique human monoclonal antibodies against a novel cytokine identified by Kuchroo Laboratory. Zumutor will use its proprietary antibody discovery platform INABLR® to identify novel antibody clones against the cytokine

–

Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced that it has signed an agreement with Zumutor Biologics, Inc., to manufacture Zumutor’s lead candidate, ZM008, for the treatment of solid tumors